Ala-Glu-Asp • AED Peptide • T-31
Cartalax is a synthetic three-amino-acid peptide developed within the Khavinson peptide-bioregulator research program. It has been studied mainly in laboratory and animal models involving fibroblasts, cartilage-related cells, connective tissue, kidney cells, and cellular-aging markers, but robust controlled human evidence is absent.
Cartalax is a synthetic tripeptide made from alanine, glutamic acid, and aspartic acid. Its sequence is Ala-Glu-Asp, which is why it is also called AED peptide or T-31.
It belongs to the family of short peptide bioregulators associated with Vladimir Khavinson’s research program at the St. Petersburg Institute of Bioregulation and Gerontology. Published descriptions extend beyond cartilage to fibroblasts and related connective-tissue cells found in skin, blood vessels, kidneys, and other tissues.
Khavinson-related research proposes that certain short peptides may enter cells and influence chromatin-associated gene-expression processes. That remains a research hypothesis rather than a clinically established human mechanism.
Studies of the AED sequence report changes in renewal, senescence, and extracellular-matrix markers in cultured cells. These laboratory findings do not establish a clinical tissue-repair effect.
These potential effects come primarily from cell-culture and animal work and should not be interpreted as proven clinical benefits.
Experimental work has examined chondrocytes, fibroblasts, extracellular-matrix markers, and tissue-breakdown enzymes.
Fibroblast studies report changes involving proliferation, collagen-related markers, and matrix metalloproteinases.
Studies report changes in senescence and apoptosis markers including p16, p21, p53, and SIRT6.
Aging-model research has examined proliferation and senescence markers in kidney cells and tissue cultures.
This is a community peptide-bioregulator protocol, not an FDA-approved regimen or a schedule validated in controlled human trials.
Sign in or create a free account to view this content.
Wash your hands, clean the work surface, and wipe both vial stoppers with alcohol. Allow them to dry.
Use a new sterile syringe and needle to direct the selected volume of compatible diluent down the inside wall of the vial.
Swirl or roll the vial until the contents dissolve; do not shake.
Store refrigerated at 2–8°C (36–46°F) and protected from light when the product instructions support this. Record the reconstitution date in your research journal.
These combinations are theoretical or community based. No controlled studies have established their safety or effectiveness.
Both belong to the Khavinson bioregulator framework but are positioned around different tissue targets. Concurrent use is unstudied.
BPC-157 is discussed for active injury recovery; Cartalax is positioned as connective-tissue maintenance. No combination study exists.
Both are discussed around fibroblasts and extracellular-matrix biology through different proposed mechanisms.
Cartalax is made from naturally occurring amino acids, but that does not establish safety for an injected research product. Human tolerability data is sparse, product quality may vary, and long-term safety has not been characterized.
We view Cartalax as a Khavinson bioregulator focused on fibroblast activity and extracellular matrix regulation. Laboratory work on the AED sequence points to changes in cell-renewal and matrix-related markers, but it does not yet show that Cartalax improves joint comfort or mobility in people.
Community feedback is generally positive, with users noting gradual improvements in how their joints feel and function. Results build over time rather than appearing overnight. We are interested in its connective-tissue research, but would not treat stack reports as proof of enhanced recovery or long-term joint benefit.
Peptide Protocols
Send us a message and we’ll reply to the email address you provide.